|

Tafasitamab Clinical Trials

15 actively recruiting trials across 10 locations

Also known as: 1422527-84-1, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Dimer, Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain,, Immunoglobulin +7 more

Pipeline

Early 1: 1Phase 1: 1Phase 2: 9Phase 1/2: 3

Top Sponsors

  • University of Washington2
  • M.D. Anderson Cancer Center2
  • Incyte Corporation2
  • University of Cologne1
  • SWOG Cancer Research Network1

Indications

  • Cancer14
  • Grade 3b Follicular Lymphoma2
  • High-grade B-cell Lymphoma2
  • Diffuse Large B-Cell Lymphoma2
  • Systemic Sclerosis1

Other3 trials

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Phase 2
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
Phase 2
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Early 1

Houston, Texas2 trials

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

M D Anderson Cancer Center

Phase 2
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

MD Anderson Cancer Center

Phase 1/2

Seattle, Washington2 trials

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Birmingham, Alabama1 trial

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Alabama Oncology

Tucson, Arizona1 trial

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Banner University Medical Center - Tucson

Phase 2

Miami, Florida1 trial

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

University of Miami

Phase 1/2

Minneapolis, Minnesota1 trial

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Masonic Cancer Center

Phase 2

Rochester, Minnesota1 trial

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Mayo Clinic in Rochester

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma

Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Phase 2

Columbus, Ohio1 trial

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2

Portland, Oregon1 trial

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

OHSU Knight Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.